Skip to Content
Søg Menu
9.-13. september 2022

Vi var på ESMO 2022 I European Society for Medical Oncology

Seneste fra ESMO 2022

Højdosis strålebehandling ved småcellet lungekræft i begrænset stadium

  • / Bjørn Henning Grønberg

SABCS Kongresside

Her finder du abstracts, online artikler, MEDtalks med internationale og nationale key opinion leaders fra SABCS

Se mere

MCED blood test – a gamechanger for early cancer detection for cancer

/ Hæmatologi / BestPractice Nordic

Air pollution and lung cancer in never-smoking people 

/ Onkologi / BestPractice Nordic

Tumor-infiltrating lymphocytes improves PFS in metastatic melanoma

/ Onkologi / BestPractice Nordic

Combination of abemaciclib and trastuzumab +/- fulvestrant improved OS in women with HR+, HER2+ advanced breast cancer  

/ Onkologi / BestPractice Nordic

A major threat to human health

/ Onkologi / BestPractice Nordic

MEDtalks fra ESMO 2022

ESMO20: Update om lungecancer

/ Onkologi / Bjørn Henning Grønberg

ESMO20: Improved OS rate for metastatic, PD-L1-positive lung cancer patients

/ Onkologi / Julie Brahmer

ESMO20: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer

/ Onkologi / Stephen Johnston

ESMO20: KEYNOTE 590 will change practice for patients with oesophagus Cancer

/ Onkologi / Ken Kato

ESMO20: New first-line treatment option for metastatic kidney cancer

/ Onkologi / Toni K. Choueiri
Se oversigt

Endocrine Response for Routine Decision-making on Chemotherapy use in HR+/HER2-N0-1 Early Breast Cancer

/ Onkologi / Nadia Harbeck

Current landscape in the immuno-oncology treatment of non-melanoma skin cancers

/ Onkologi / Paolo Antonio Ascierto

Sexual health in long-term breast cancer survivors

/ Onkologi / Solveig Katrine Smedsland

ICON trial update: Ipi+Nivo combination with chemotherapy does not improve survival

/ Onkologi / Jon Amund Kyte

The clinical value of circulating tumor DNA in bladder and renal cancer

/ Onkologi / Lars Dyrskjøt Andersen

Outstanding results of ovarian cancer treatment

/ Onkologi / Clare Scott

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

/ Onkologi / Kristina Lindemann

Efficacy of trastuzumab-deruxtecan therapy in HER2-positive breast cancer

/ Onkologi / Angelika Starzer

ESMO Highlights: Promising data for the frontline treatment of gynecologic cancer

/ Onkologi / Kristina Lindemann

ESMO Highlights: Increase awareness of supportive and palliative care for patients with cancer

/ Onkologi / Christina H. Ruhlmann

Tema: Lungecancer

First-line atezolizumab treatment significantly improves overall survival in patients with NSCLC and not eligible for a platinum-containing regimen

  • / Siow Ming Lee

Can High-Intensity Aerobic exercise give patients with cancer better survival by stimulating the immune system?

/ Onkologi / Gitte Holmen Olofsson

Langtidsholdbar og robust overlevelsesdata for stadie IV-NSCLC – 3 års update fra CheckMate 9LA studiet

/ Onkologi / Edyta Maria Urbanska

Betydning af screening og selektering for overlevelsen ved lungecancer

/ Onkologi / Torben Riis Rasmussen

ESMO Highlights: Practical changes for treatment of lower gastrointestinal tumors

/ Onkologi / Marco Gerlinger

Klinik for senfølger efter kræft: 80% af de besøgende er kvinder

/ Almen praksis / Karin Brochsted Dieperink

Abstracts fra ESMO 2022

PARP inhibitors are showing promising results in treating ovarian cancer 

/ BestPractice Nordic
ESMO22Gynækologisk cancer

Doublet immune therapy for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy 

/ BestPractice Nordic
ESMO22Nyrecancer

ESMO 2022 –” Understanding the disease to provide better care for cancer patients”  

/ BestPractice Nordic
ESMO22
Hent flere

Faglig test – Pulmonalt planocellulært karcinom

Test din viden om pulmonalt planocellulært karcinom

Tag testen her

ESMO 2021

Maintenance olaparib rechallenge in patients with ovarian carcinoma benefit outcomes

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Silvia Stacchiotti

Global consensus: Management of epithelioid hemangioendothelioma

/ Silvia Stacchiotti
ESMO21Cancer Play the Video
Eric Pujade-Lauraine

PARP inhibitor olaparib shows significant improvement in PFS for patients with relapsed platinum-sensitive ovarian cancer

/ Eric Pujade-Lauraine
ESMO21Gynækologisk cancer Play the Video
Alan Celik

HER2-positiv brystcancer – fremtidige behandlingsmuligheder

/ Alan Celik
ESMO21Brystcancer Play the Video
Lene Bæksgaard Jensen

Opdatering på CheckMate 649-studiet

/ Lene Bæksgaard
ESMO21Kemoterapi Play the Video
Dana Chase

High-risk factors in patients with advanced ovarian cancer impact survival

/ Dana Chase
ESMO21Gynækologisk cancer Play the Video
Hent flere

MEDtalks fra ESMO 2020

PIONeeR-studiet bringer os tættere på forståelsen af resistens mod PD-1/L1 inhibitorer

LungecancerESMO20

Lovende effekt på hjernemetastaser placerer osimertinib som adjuverende behandling af EGFR-positiv ikke-småcellet lungecancer

HjernemetastaserLungecancerESMO20

Lorlatinib har potentiale til at blive ny førstelinjebehandling til lokal fremskreden og metastatisk ALK positiv NSCLC

NSCLCLungecancerESMO20

ESMO20: Kombinationsbehandling i første linje ved nyrecancer

/ Daniel Heinrich
ESMO20Nyrecancer Play the Video

Sacituzumab Govitecan er en ny lovende behandling til 2/3 linje triple-negativ avanceret brystkræft

BrystcancerESMO20

Resultaterne fra Solar-1 lover godt for alpelisib plus fulvestrant til patienter med HR-positiv, HER2-negativ avanceret brystkræft med PI3KCA mutationer

BrystcancerESMO20
Se mere fra ESMO
Back to top